WebCRL-2322 ™. HCC1187 is a mammary gland epithelial cell that was isolated from a 41-year-old, White female patient with ductal carcinoma TNM Stage IIA, grade 3. The cell can be … WebOrde nline a ww.atcc.org al 800.638.6597 703.365.2700 ontac ou oca istributor. Page 7 †Fo escriptio h equenc ariatio omenclatur leas efe o e Dunne T n Antona˜ake SE 2000) um Mutat 15:7-12. CDKN2A Cyclin-dependent kinase inhibitor 2A (CDKN2A) is a tumor suppressor gene, encoding three splice variants, two of
Figures and data in Dependency of human and murine LKB1 ... - eLife
WebL-O2细胞系 复苏中心发货时间短细胞来源说明:细胞主要来源ATCC、DSMZ、ECACC、RIKEN、INCell、promocell、ScienCell、ECACC、JCRB、KCLB、Asterand、ICLC以及少数国外著名大学建系细胞常规培养传代流程(请严格遵照无菌操作) WebH2122; H-2122; NCIH2122. Accession. CVCL_1531. Resource Identification Initiative. To cite this cell line use: NCI-H2122 (RRID:CVCL_1531) Comments. Part of: Cancer … ohio and michigan paper
AddexBio Product Detail - H2122 Cells
WebAdd 6.0 to 8.0 mL complete growth medium and aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new culture vessels. Incubate cultures at 37°C. Interval: every 6 to 8 days. Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended. Medium Renewal: 2 to 3 times per week. WebCompound Viability screens Drug sensitivity AUC (Sanger GDSC1) Drug sensitivity AUC (Sanger GDSC2) Drug sensitivity IC50 (Sanger GDSC1) Drug sensitivity IC50 (Sanger GDSC2) Drug sensitivity AUC (CTD^2) Drug sensitivity (PRISM Repurposing Primary Screen) Drug sensitivity AUC (PRISM Repurposing Secondary Screen) Drug sensitivity … WebJun 18, 2024 · MOR, A549, NCI-H441, and NCI-H2122 were plated at 12,000–50,000 cells per well in 24-well plates. 24 hrs after cell plating drug was added at a two-fold dilution series into wells containing either 0.25 μM cobimetinib or DMSO. Treatment media was replaced every three to four days. myhealthcare technologies private limited